Rystiggo MG denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits the Quantity of Rystiggo (rozanolixizumab-noli) — and How to Appeal

Rystiggo is an FcRn antagonist approved for generalized myasthenia gravis (gMG) in adults who are anti-AChR or anti-MuSK antibody positive. Cigna's quantity-limit restriction reflects the dosing schedule defined in the FDA-approved prescribing information: the label specifies a fixed treatment cycle with a defined number of infusions per cycle and a defined interval between cycles. When a claim falls outside those parameters — for example, a cycle starting sooner than the label permits — the system flags it as exceeding quantity limits.

### Why This Is Appealable

Quantity-limit denials are among the most successfully overturned on appeal when the prescriber can demonstrate that (a) the requested quantity exactly matches the FDA-approved dosing schedule and (b) any deviation is supported by a documented clinical rationale. If Cigna's own published coverage policy imposes limits narrower than the FDA label, federal law gives you the right to challenge that restriction.

### Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair review. For a non-urgent denial, the plan must decide within 60 days of receiving your appeal. For urgent/concurrent care, an expedited track applies and the deadline shortens significantly — confirm the exact timeline in your Summary Plan Description.
• External review: If the internal appeal fails, you may request an independent external review. Under ACA §2719, most non-grandfathered group and individual plans must offer this. The external-review request window is typically around four months from the final internal denial notice — check your denial letter for the exact deadline.
• State-regulated plans: If your Cigna plan is fully insured (not self-funded ERISA), your state's insurance commissioner also has jurisdiction and may offer an independent medical review process.

### Appeal Process and Timeline

1. Request the complete denial file and Cigna's current Rystiggo coverage policy. 2. Have your neurologist submit a detailed medical-necessity letter within 30 days of denial. 3. File the written internal appeal with all supporting documents. 4. If upheld, file for external review promptly — do not wait until the deadline.

### Documentation to Gather

• Diagnosis confirmation: Anti-AChR or anti-MuSK antibody test results; neurologist-confirmed gMG diagnosis.
• Clinical severity: Quantitative MG score or equivalent functional assessment from the chart showing disease impact.
• Requested quantity vs. label: A side-by-side showing the exact quantity requested matches the FDA prescribing information dosing cycle — obtain the label from DailyMed (dailymed.nlm.nih.gov).
• Prescriber letter: Neurologist explains the medical necessity of this quantity and timing, referencing the applicable guideline organization (e.g., the American Association of Neuromuscular and Electrodiagnostic Medicine) without inventing numbers.

### Criteria-Mapping Structure

Print Cigna's Rystiggo coverage policy. List every quantity-limit criterion. Next to each, write the exact chart fact or lab result that satisfies it. Present this table in your appeal letter. Reviewers respond to organized, criterion-by-criterion responses — do not submit a narrative alone.